CClinicalTrials.gg
Sign In
CompletedNCT00852865Updated May 1, 2009

Lactobacillus Farciminis and Hyperalgesia

A Phase 1 interventional study of Lactobacillus farciminis and Placebo in Inflammation and Pain, sponsored by Lallemand SAS. Completed at 1 site in France. Open to participants aged 18 Years to 60 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2009-05-01.

Sponsored by Lallemand SAS · Phase 1, Interventional, and Treatment

Phase
Phase 1
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

We want to analyse a possible effect of o dialy consumption of Lactobacillus farciminis on a hyperalgesia on response to thermal stimulation. A comparaison of results before and after three weeks of treatment will be made.

02

Conditions studied

  • Inflammation
  • Pain

Keywords

  • Inflammation
  • Pain
03

In context

Hyperalgesia

152 studies on the registry are indexed under Hyperalgesia; 13 are open to participants now.

This study's enrollment of 48 is above the median of 42 across 127 interventional studies indexed under Hyperalgesia.

Browse Hyperalgesia studies →

Lead sponsor

Lallemand SAS is the lead sponsor of 2 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Inclusion criteria

  • healthy volunteers

Exclusion criteria

Exclusion Criteria:

  • consumption of yogurts
05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    1

    24 healthy volunteers consuming L.farciminis during three weeks

    Drug: Lactobacillus farciminis

  • Placebo comparator
    2

    24 healthy volunteers consuming placebo during three weeks

    Drug: Placebo

Interventions

  • DrugLactobacillus farciminis

    1 capsule per day. Each capsule containing 4\*109 CFU

  • DrugPlacebo

    1 capsule per day

06

What researchers measure

Primary outcomes

  1. Measurement of the mchanical pain threshold in primary and secondary areas by using a punctate stimulus.

Secondary outcomes

  1. Measurement of cutaneous temperature of hyperalgesia areas

07

Study locations

1 site
  • Cpc / Cic-Inserm 501
    Clermont-Ferrand, 63000, France
08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on May 1, 2009, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00852865
Lead sponsor
Lallemand SAS
First posted
Feb 27, 2009
Start date
Feb 2009
Primary completion
Apr 2009
Completion
Apr 2009
Last update
May 1, 2009

Study contacts

Claude DUBRAY, Professor
principal investigator · CPC/CIC-INSERM 501

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2009. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Other studies in this condition

Hyperalgesia→

Other studies from this sponsor

Lallemand SAS

Start the discussion